Acetazolamide
Acetazolamide (acetazolamide) is a small molecule pharmaceutical. Acetazolamide was first approved as Diamox on 1982-01-01. It is used to treat altitude sickness, glaucoma, and seizures in the USA. The pharmaceutical is active against carbonic anhydrase 7. In addition, it is known to target carbonic anhydrase 14, carbonic anhydrase 12, carbonic anhydrase 1, carbonic anhydrase 13, and carbonic anhydrase 4.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
Acetazolamide (discontinued: Acetazolamide, Diamox)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| acetazolamide | ANDA | 2025-01-03 |
| acetazolamide extended-release | ANDA | 2024-09-27 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| altitude sickness | EFO_1000782 | D000532 | T70.29 |
| glaucoma | EFO_0000516 | D005901 | H40 |
| seizures | HP_0002069 | D012640 | G40.4 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
Code | Description |
|---|---|
| J1120 | Injection, acetazolamide sodium, up to 500 mg |
Clinical
Clinical Trials
171 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Altitude sickness | D000532 | EFO_1000782 | T70.29 | 4 | 2 | 3 | 16 | 6 | 30 |
| Sleep apnea syndromes | D012891 | HP_0010535 | G47.3 | 2 | 12 | 1 | 9 | 4 | 25 |
| Heart failure | D006333 | HP_0001635 | I50 | — | — | 5 | 11 | 5 | 21 |
| Obstructive sleep apnea | D020181 | EFO_0003918 | G47.33 | 3 | 9 | 1 | 4 | 1 | 15 |
| Apnea | D001049 | HP_0002104 | R06.81 | — | 7 | 1 | 5 | 2 | 15 |
| Hypoxia | D000860 | HP_0012418 | R09.02 | 1 | — | 1 | 10 | 1 | 13 |
| Chronic obstructive pulmonary disease | D029424 | EFO_0000341 | J44.9 | — | — | 3 | 9 | — | 12 |
| Obstructive lung diseases | D008173 | HP_0006536 | — | — | — | 2 | 9 | — | 11 |
| Lung diseases | D008171 | HP_0002088 | J98.4 | — | — | 2 | 8 | — | 10 |
| Glaucoma | D005901 | EFO_0000516 | H40 | — | — | 1 | 3 | 2 | 6 |
Show 26 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hypertension | D006973 | EFO_0000537 | I10 | 1 | 6 | 5 | — | 1 | 10 |
| Intracranial hypertension | D019586 | EFO_1000992 | — | 1 | 1 | 3 | — | 1 | 5 |
| Pseudotumor cerebri | D011559 | EFO_1001132 | G93.2 | 1 | 1 | 3 | — | — | 4 |
| Stroke | D020521 | EFO_0000712 | I63.9 | — | 2 | 1 | — | 1 | 4 |
| Hypotension | D007022 | EFO_0005251 | I95 | 1 | — | 1 | — | — | 2 |
| Retinal artery occlusion | D015356 | EFO_1001154 | H34.1 | — | — | 1 | — | — | 1 |
| Hemodilution | D006438 | — | — | — | — | 1 | — | — | 1 |
| Visual acuity | D014792 | — | — | — | — | 1 | — | — | 1 |
| Fibrinolysis | D005342 | — | — | — | — | 1 | — | — | 1 |
| Neurocysticercosis | D020019 | — | — | — | 1 | 1 | — | — | 1 |
Show 12 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Macular edema | D008269 | — | — | — | 3 | — | — | — | 3 |
| Chronic pain | D059350 | HP_0012532 | — | — | 2 | — | — | — | 2 |
| Macular degeneration | D008268 | EFO_0001365 | H35.30 | — | 2 | — | — | — | 2 |
| Diabetic retinopathy | D003930 | EFO_0003770 | — | — | 2 | — | — | — | 2 |
| Ocular hypertension | D009798 | EFO_1001069 | H40.0 | — | 1 | — | — | 1 | 2 |
| Brain edema | D001929 | EFO_1000845 | G93.6 | — | 1 | — | — | 1 | 2 |
| Cerebrospinal fluid leak | D065634 | — | G96.0 | — | 2 | — | — | — | 2 |
| Hydrocephalus | D006849 | HP_0000238 | G91 | — | 2 | — | — | — | 2 |
| Normal pressure hydrocephalus | D006850 | EFO_1001065 | G91.2 | — | 2 | — | — | — | 2 |
| Lung neoplasms | D008175 | HP_0100526 | C34.90 | 2 | 1 | — | — | — | 2 |
Show 27 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 1 | — | — | — | 2 | 3 |
| Obesity | D009765 | EFO_0001073 | E66.9 | 1 | — | — | — | 1 | 2 |
| Pure autonomic failure | D054970 | — | — | 1 | — | — | — | — | 1 |
| Orthostatic hypotension | D007024 | — | I95.1 | 1 | — | — | — | — | 1 |
| Glioma | D005910 | EFO_0000520 | — | 1 | — | — | — | — | 1 |
| Prostatic neoplasms | D011471 | — | C61 | 1 | — | — | — | — | 1 |
| Postoperative pain | D010149 | — | G89.18 | 1 | — | — | — | — | 1 |
| Cognition | D003071 | EFO_0003925 | — | 1 | — | — | — | — | 1 |
| Exercise tolerance | D017079 | — | — | 1 | — | — | — | — | 1 |
| Small cell lung carcinoma | D055752 | — | — | 1 | — | — | — | — | 1 |
Show 3 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Sickle cell anemia | D000755 | EFO_0000697 | D57 | — | — | — | — | 2 | 2 |
| Migraine disorders | D008881 | EFO_0003821 | G43 | — | — | — | — | 2 | 2 |
| Headache | D006261 | HP_0002315 | R51 | — | — | — | — | 2 | 2 |
| Acute liver failure | D017114 | HP_0004448 | — | — | — | — | — | 2 | 2 |
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | — | — | — | — | 2 | 2 |
| Cerebral infarction | D002544 | — | I63 | — | — | — | — | 2 | 2 |
| Dementia | D003704 | EFO_0003862 | F03 | — | — | — | — | 2 | 2 |
| Anemia | D000740 | HP_0001903 | D64.9 | — | — | — | — | 1 | 1 |
| Thalassemia | D013789 | EFO_1001996 | D56 | — | — | — | — | 1 | 1 |
| Leukoencephalopathies | D056784 | HP_0002352 | — | — | — | — | — | 1 | 1 |
Show 19 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Acetazolamide |
| INN | acetazolamide |
| Description | Acetazolamide is a sulfonamide, a member of thiadiazoles and a monocarboxylic acid amide. It has a role as a diuretic, an anticonvulsant and an EC 4.2.1.1 (carbonic anhydrase) inhibitor. It is a conjugate acid of an acetazolamide(1-). It derives from a hydride of a 1,3,4-thiadiazole. |
| Classification | Small molecule |
| Drug class | carbonic anhydrase inhibitors |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CC(=O)Nc1nnc(S(N)(=O)=O)s1 |
Identifiers
| PDB | — |
| CAS-ID | 59-66-5 |
| RxCUI | — |
| ChEMBL ID | CHEMBL20 |
| ChEBI ID | 27690 |
| PubChem CID | 1986 |
| DrugBank | DB00819 |
| UNII ID | O3FX965V0I (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
No data
Estimated US medical usage
Acetazolamide
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 16,209 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
2,988 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use